A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

Axsome Therapeutics said it's dopamine and norepinephrine reuptake inhibitor solriamfetol (Sunosi), approved for excessive ...

Axsome Therapeutics said Tuesday that a Phase 3 trial for its narcolepsy drug Sunosi failed to meet its primary goal in major ...

Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive impairment, 2-week solriamfetol led to cognitive function improvement on three tests/scales, according to ...

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes ...

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...

Axsome Therapeutics said the lower dose of its sleep disorder drug Sunosi met the primary endpoint in a late-stage test of ...

Sunosi is a prescription drug that’s prescribed for excessive daytime sleepiness (EDS) in certain adults. It is a controlled substance. Sunosi is a part of the class of drugs called dopamine ...